The HUMIRA Tool for patients with RA, AS, or PsA

HUMIRA is indicated for:

• Reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active RA. Can be used alone or in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs). When used as first-line treatment in recently diagnosed patients who have not been previously treated with MTX, HUMIRA should be given in combination with MTX. Can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is contraindicated.
• Reducing the signs and symptoms in adult patients with active AS who have had an inadequate response to conventional therapy.
• Reducing the signs and symptoms of active arthritis and inhibiting the progression of structural damage and improving the physical function in adult PsA patients. Can be used in combination with MTX in patients who do not respond adequately to MTX alone.

Consult the Product Monograph at abbvie.ca/content/dam/abbviecorp/ca/en/docs/HUMIRA_PM_EN.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, conditions of clinical use, and storage and handling. The Product Monograph is also available by calling 1-888-704-8271.